May 17, 2011 08:59 ET

Equity Research on GlaxoSmithKline plc and Johnson & Johnson - Several Promising Trends for Drug Manufacturers - Major Sector

NEW YORK, NY--(Marketwire - May 17, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Major industry and are offering free analytical research on GlaxoSmithKline plc (NYSE: GSK) and Johnson & Johnson (NYSE: JNJ). Register with us today at to have free access to this research or speak to one of our pros at

There are several promising trends for the Drug Manufacturers - Major sector that have helped shield them from too harsh a decline during the recession and will likely continue to prop the sector in the future. The first is the growth of emerging markets. While these countries are quickly modernizing, they still represent a disproportionately small portion of global pharmaceutical sales. This is not because they are healthier but because there has historically been a correlation between disposable income and the uptake of medicines. Now that these economies are feeling the expansion of an affluent middle class, it is likely the population will look to spend its extra cash on improving the quality of their lives. Get instant analyses of GlaxoSmithKline plc and Johnson & Johnson from live, real-time experts standing by at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning GlaxoSmithKline plc and Johnson & Johnson then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Another helpful trend has been the aging generation of baby boomers that are heading into the peak period of their lives for pharmaceutical use. One of the biggest opportunities for the sector is in the development of a cancer cure. As over a $20 billion per year market, an effective and non-invasive cancer treatment would represent an incredibly lucrative, if not humanitarian, product for the sector. Several companies, including GlaxoSmithKline plc are using a new approach to fighting the disease that attempts to reprogram affected DNA. GlaxoSmithKline plc report is accessible for free by registering today at

The government is always a major headwind to earnings in the sector. Whether the FDA is hesitant to approve new drugs or federal prosecutors are suing companies for improper marketing practices, the involvement of the government can certainly weigh on profits. This could be seen in the works for Johnson & Johnson as prosecutors seek $1 billion from the company for improper marketing of its drug Risperdal. Johnson & Johnson report is accessible for free by registering today at

The two Drug Manufacturers - Major stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information